Accelerating Research into Mitochondrial Diseases Through the Acquisition of Myotbridge
A standalone M&A transaction involving the exercise of the option to make マイトブリッジ a wholly owned subsidiary and accelerate research and development in mitochondrial diseases through its acquisition.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.